Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2024

Description

Liposomal Doxorubicin Market Growth & Trends:

The global liposomal doxorubicin market size is expected to reach USD 1.89 billion by 2030, registering a CAGR of 6.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of various pipeline products awaiting approval by the U.S. FDA and European Medicines Agency is one of the key attributes of this market. The first liposomal doxorubicin formulation was launched in 1995, namely Doxil/Caelyx by Janssen Products and LP & Myocet by Teva Pharmaceutical Laboratories. Doxil, the brand name of liposomal doxorubicin, is under development, and post its commercialization, the product is expected to create significant value over the next 3 to 4 years.

The increasing U.S. FDA approval for drug production is also anticipated to boost the market. The increasing indication of these drugs for various conditions such as AIDS-related Kaposi sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand. The technological advancements in the drugs formulations to overcome the adverse effects on health and also introduction of various types of medication delivery systems, such as coated nanoparticles, are some of the pivotal factors impelling the demand for the drug.

Liposomal doxorubicin is primarily approved for the treatment of myeloma, Kaposi sarcoma, and ovarian cancer. However, due to its wide usage in other conditions as well, in 2015, breast cancer accounted for the maximum revenue of 21.2%. The increasing prevalence of breast cancer is leading to growing demand for chemotherapy treatment, which accounts for the majority of revenue share. Besides breast carcinoma, ovarian cancer, multiple myeloma, and liver cancer also held a significant share in 2015. The use of doxorubicin for liver carcinoma treatment is rapidly growing, and this application is expected to grow with the fastest CAGR of 7.8% over the forecast period.

Liposomal Doxorubicin Market Report Highlights:

The increasing number of mergers & acquisitions and partnerships for clinical trials on technologically advanced doxorubicin formulations will boost market growth
Increasing investment in Asia Pacific pertaining to the R&D, improving healthcare infrastructure, and heightened patient cognizance regarding targeted cancer therapies and chemotherapy will drive regional market growth
The lipodox segment dominated the market with 40.0% share in 2023 and is expected to grow at a CAGR of 7.3% from 2024 to 2030.

Product Code: GVR-1-68038-743-8

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Liposomal Doxorubicin Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Liposomal Doxorubicin Market: Product Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Liposomal Doxorubicin Market: Product Movement Analysis, 2023 & 2030 (USD Million)
4.3. Doxil/Caelyx
- 4.3.1. Doxil/Caelyx Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Lipodox
- 4.4.1. Lipodox Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Myocet
- 4.5.1. Myocet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Others
- 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liposomal Doxorubicin Market: Application Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Liposomal Doxorubicin Market: Application Movement Analysis, 2023 & 2030 (USD Million)
5.3. Breast Cancer
- 5.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. Ovarian Cancer
- 5.4.1. Ovarian Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. AIDS-Related Kaposi's Sarcoma
- 5.5.1. AIDS-Related Kaposi's Sarcoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Multiple Myeloma
- 5.6.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Other Solid Tumors
- 5.7.1. Other Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Liposomal Doxorubicin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
6.3. Hospital Pharmacies
- 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Retail Pharmacies
- 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Online Pharmacies
- 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis

7.1. Liposomal Doxorubicin Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
- 7.2.1. North America Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
  - 7.2.3.1. Canada Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
- 7.3.1. Europe Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
  - 7.3.2.1. UK Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
  - 7.3.3.1. Germany Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
  - 7.3.4.1. France Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
  - 7.3.5.1. Italy Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
  - 7.3.6.1. Spain Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
  - 7.3.9.1. Norway Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
  - 7.4.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
  - 7.4.3.1. China Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
  - 7.4.4.1. India Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Australia
  - 7.4.5.1. Australia Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
- 7.5.1. Latin America Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
  - 7.6.4.1. UAE Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.7. Recent Developments & Impact Analysis by Key Market Participants
7.8. Company Categorization
7.9. Company Heat Map Analysis
7.10. Company Profiles
- 7.10.1. Sun Pharmaceutical Industries Ltd.
  - 7.10.1.1. Participant's Overview
  - 7.10.1.2. Financial Performance
  - 7.10.1.3. Product Benchmarking
  - 7.10.1.4. Recent Developments/ Strategic Initiatives
- 7.10.2. Johnson & Johnson Services, Inc.
  - 7.10.2.1. Participant's Overview
  - 7.10.2.2. Financial Performance
  - 7.10.2.3. Product Benchmarking
  - 7.10.2.4. Recent Developments/ Strategic Initiatives
- 7.10.3. Merck & Co., Inc.
  - 7.10.3.1. Participant's Overview
  - 7.10.3.2. Financial Performance
  - 7.10.3.3. Product Benchmarking
  - 7.10.3.4. Recent Developments/ Strategic Initiatives
- 7.10.4. Cipla
  - 7.10.4.1. Participant's Overview
  - 7.10.4.2. Financial Performance
  - 7.10.4.3. Product Benchmarking
  - 7.10.4.4. Recent Developments/ Strategic Initiatives
- 7.10.5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
  - 7.10.5.1. Participant's Overview
  - 7.10.5.2. Financial Performance
  - 7.10.5.3. Product Benchmarking
  - 7.10.5.4. Recent Developments/ Strategic Initiatives
- 7.10.6. Lupin
  - 7.10.6.1. Participant's Overview
  - 7.10.6.2. Financial Performance
  - 7.10.6.3. Product Benchmarking
  - 7.10.6.4. Recent Developments/ Strategic Initiatives
- 7.10.7. Cadila Pharmaceuticals
  - 7.10.7.1. Participant's Overview
  - 7.10.7.2. Financial Performance
  - 7.10.7.3. Product Benchmarking
  - 7.10.7.4. Recent Developments/ Strategic Initiatives
- 7.10.8. SRS Life Sciences
  - 7.10.8.1. Participant's Overview
  - 7.10.8.2. Financial Performance
  - 7.10.8.3. Product Benchmarking
  - 7.10.8.4. Recent Developments/ Strategic Initiatives
- 7.10.9. GSK plc.
  - 7.10.9.1. Participant's Overview
  - 7.10.9.2. Financial Performance
  - 7.10.9.3. Product Benchmarking
  - 7.10.9.4. Recent Developments/ Strategic Initiatives
- 7.10.10. Pfizer Inc.
  - 7.10.10.1. Participant's Overview
  - 7.10.10.2. Financial Performance
  - 7.10.10.3. Product Benchmarking
  - 7.10.10.4. Recent Developments/ Strategic Initiatives
- 7.10.11. Sanofi
  - 7.10.11.1. Participant's Overview
  - 7.10.11.2. Financial Performance
  - 7.10.11.3. Product Benchmarking
  - 7.10.11.4. Recent Developments/ Strategic Initiatives
- 7.10.12. Sigma-Aldrich Co.
  - 7.10.12.1. Participant's Overview
  - 7.10.12.2. Financial Performance
  - 7.10.12.3. Product Benchmarking
  - 7.10.12.4. Recent Developments/ Strategic Initiatives

Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030